FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000949367> ?p ?o ?g. }

• W2000949367 endingPage "735" @default.
• W2000949367 startingPage "731" @default.
• W2000949367 abstract "Study Objectives: Recurrent chylothorax as a complication of lymphoma has had unsatisfactory outcomes. Serial thoracentesis, tube thoracostomy, and pleurodesis via chest tube have been ineffective and compromise the nutritional and immune status of the patient. Medical thoracoscopic talc pleurodesis has been safe and effective in the treatment of some other varieties of recurrent pleural effusions. Our objective was to investigate the safety and efficacy of medical thoracoscopic talc pleurodesis in the palliation of chylothorax related to lymphoma. Design: This is a report of 24 hemithoraces treated in 19 consecutive patients with lymphoma-related chylothorax, failing chemotherapy or radiation therapy. The average patient age was 55 years. Interventions: Medical thoracoscopy was performed under local anesthesia and conscious sedation in a bronchoscopy suite. Sedation included midazolam (mean dose, 6 mg; range, 2-14 mg) with either meperidine (mean dose, 94 mg; range 25-140 mg), or morphine (mean dose, 18 mg; range 4-40 mg). Pleurodesis was performed with insufflation of sterile asbestos-free talc, (4-8 g). After pleurodesis, chest tubes were placed, with the mean duration of chest tube placement being 4 days, range 3 to 10 days. Results: One patient died a few days after the procedure due to causes related to the primary disease process. Follow-up was for at least 90 days following the procedure. Patients were assessed at 30, 60, and 90 days following the procedure. At each of these endpoints, all patients remaining alive were without recurrence of pleural effusions, which was confirmed by chest radiography. Eight patients in the series died of the effects of their malignancy during the 90-day evaluation interval. Complications included medication reactions in two patients (8.3%) and ARDS in one patient (4.1%). Conclusion: Many patients with lymphoma-related chylothorax are refractory to chemotherapy and/or radiation therapy. In this group, medical thoracoscopic talc pleurodesis has an acceptable complication rate and a 100% success rate in the prevention of recurrence of pleural effusions at 30, 60, and 90 days following the procedure. (CHEST 1998; 114:731–735) Abbreviations: CLL=chronic lymphocytic leukemia; MCT=medium chain triglyceride Study Objectives: Recurrent chylothorax as a complication of lymphoma has had unsatisfactory outcomes. Serial thoracentesis, tube thoracostomy, and pleurodesis via chest tube have been ineffective and compromise the nutritional and immune status of the patient. Medical thoracoscopic talc pleurodesis has been safe and effective in the treatment of some other varieties of recurrent pleural effusions. Our objective was to investigate the safety and efficacy of medical thoracoscopic talc pleurodesis in the palliation of chylothorax related to lymphoma. Design: This is a report of 24 hemithoraces treated in 19 consecutive patients with lymphoma-related chylothorax, failing chemotherapy or radiation therapy. The average patient age was 55 years. Interventions: Medical thoracoscopy was performed under local anesthesia and conscious sedation in a bronchoscopy suite. Sedation included midazolam (mean dose, 6 mg; range, 2-14 mg) with either meperidine (mean dose, 94 mg; range 25-140 mg), or morphine (mean dose, 18 mg; range 4-40 mg). Pleurodesis was performed with insufflation of sterile asbestos-free talc, (4-8 g). After pleurodesis, chest tubes were placed, with the mean duration of chest tube placement being 4 days, range 3 to 10 days. Results: One patient died a few days after the procedure due to causes related to the primary disease process. Follow-up was for at least 90 days following the procedure. Patients were assessed at 30, 60, and 90 days following the procedure. At each of these endpoints, all patients remaining alive were without recurrence of pleural effusions, which was confirmed by chest radiography. Eight patients in the series died of the effects of their malignancy during the 90-day evaluation interval. Complications included medication reactions in two patients (8.3%) and ARDS in one patient (4.1%). Conclusion: Many patients with lymphoma-related chylothorax are refractory to chemotherapy and/or radiation therapy. In this group, medical thoracoscopic talc pleurodesis has an acceptable complication rate and a 100% success rate in the prevention of recurrence of pleural effusions at 30, 60, and 90 days following the procedure. (CHEST 1998; 114:731–735) Abbreviations: CLL=chronic lymphocytic leukemia; MCT=medium chain triglyceride" @default.
• W2000949367 created "2016-06-24" @default.
• W2000949367 creator A5002490395 @default.
• W2000949367 creator A5009259809 @default.
• W2000949367 date "1998-09-01" @default.
• W2000949367 modified "2023-10-16" @default.
• W2000949367 title "Medical Thoracoscopic Talc Pleurodesis for Chylothorax Due to Lymphoma" @default.
• W2000949367 cites W178740393 @default.
• W2000949367 cites W187949037 @default.
• W2000949367 cites W1891564749 @default.
• W2000949367 cites W1965387182 @default.
• W2000949367 cites W1983920079 @default.
• W2000949367 cites W1991100632 @default.
• W2000949367 cites W2010782228 @default.
• W2000949367 cites W2011571765 @default.
• W2000949367 cites W2016635221 @default.
• W2000949367 cites W2019422568 @default.
• W2000949367 cites W2028496273 @default.
• W2000949367 cites W2047659354 @default.
• W2000949367 cites W2061024737 @default.
• W2000949367 cites W2079522547 @default.
• W2000949367 cites W2081626179 @default.
• W2000949367 cites W2089777543 @default.
• W2000949367 cites W2092568526 @default.
• W2000949367 cites W2094365056 @default.
• W2000949367 cites W2327671501 @default.
• W2000949367 cites W2328259731 @default.
• W2000949367 cites W4240229537 @default.
• W2000949367 cites W4253964193 @default.
• W2000949367 cites W4323019058 @default.
• W2000949367 doi "https://doi.org/10.1378/chest.114.3.731" @default.
• W2000949367 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9743158" @default.
• W2000949367 hasPublicationYear "1998" @default.
• W2000949367 type Work @default.
• W2000949367 sameAs 2000949367 @default.
• W2000949367 citedByCount "85" @default.
• W2000949367 countsByYear W20009493672012 @default.
• W2000949367 countsByYear W20009493672013 @default.
• W2000949367 countsByYear W20009493672014 @default.
• W2000949367 countsByYear W20009493672015 @default.
• W2000949367 countsByYear W20009493672016 @default.
• W2000949367 countsByYear W20009493672017 @default.
• W2000949367 countsByYear W20009493672018 @default.
• W2000949367 countsByYear W20009493672019 @default.
• W2000949367 countsByYear W20009493672020 @default.
• W2000949367 countsByYear W20009493672021 @default.
• W2000949367 countsByYear W20009493672022 @default.
• W2000949367 countsByYear W20009493672023 @default.
• W2000949367 crossrefType "journal-article" @default.
• W2000949367 hasAuthorship W2000949367A5002490395 @default.
• W2000949367 hasAuthorship W2000949367A5009259809 @default.
• W2000949367 hasConcept C126322002 @default.
• W2000949367 hasConcept C141071460 @default.
• W2000949367 hasConcept C142724271 @default.
• W2000949367 hasConcept C2776178081 @default.
• W2000949367 hasConcept C2776212140 @default.
• W2000949367 hasConcept C2776232967 @default.
• W2000949367 hasConcept C2776517811 @default.
• W2000949367 hasConcept C2776974961 @default.
• W2000949367 hasConcept C2776979038 @default.
• W2000949367 hasConcept C2777063151 @default.
• W2000949367 hasConcept C2777407522 @default.
• W2000949367 hasConcept C2777714996 @default.
• W2000949367 hasConcept C2777799383 @default.
• W2000949367 hasConcept C2778329176 @default.
• W2000949367 hasConcept C2778373633 @default.
• W2000949367 hasConcept C2778400160 @default.
• W2000949367 hasConcept C2779056968 @default.
• W2000949367 hasConcept C2779634585 @default.
• W2000949367 hasConcept C2780496750 @default.
• W2000949367 hasConcept C42219234 @default.
• W2000949367 hasConcept C71924100 @default.
• W2000949367 hasConceptScore W2000949367C126322002 @default.
• W2000949367 hasConceptScore W2000949367C141071460 @default.
• W2000949367 hasConceptScore W2000949367C142724271 @default.
• W2000949367 hasConceptScore W2000949367C2776178081 @default.
• W2000949367 hasConceptScore W2000949367C2776212140 @default.
• W2000949367 hasConceptScore W2000949367C2776232967 @default.
• W2000949367 hasConceptScore W2000949367C2776517811 @default.
• W2000949367 hasConceptScore W2000949367C2776974961 @default.
• W2000949367 hasConceptScore W2000949367C2776979038 @default.
• W2000949367 hasConceptScore W2000949367C2777063151 @default.
• W2000949367 hasConceptScore W2000949367C2777407522 @default.
• W2000949367 hasConceptScore W2000949367C2777714996 @default.
• W2000949367 hasConceptScore W2000949367C2777799383 @default.
• W2000949367 hasConceptScore W2000949367C2778329176 @default.
• W2000949367 hasConceptScore W2000949367C2778373633 @default.
• W2000949367 hasConceptScore W2000949367C2778400160 @default.
• W2000949367 hasConceptScore W2000949367C2779056968 @default.
• W2000949367 hasConceptScore W2000949367C2779634585 @default.
• W2000949367 hasConceptScore W2000949367C2780496750 @default.
• W2000949367 hasConceptScore W2000949367C42219234 @default.
• W2000949367 hasConceptScore W2000949367C71924100 @default.
• W2000949367 hasIssue "3" @default.
• W2000949367 hasLocation W20009493671 @default.
• W2000949367 hasLocation W20009493672 @default.
• W2000949367 hasOpenAccess W2000949367 @default.
• W2000949367 hasPrimaryLocation W20009493671 @default.

• next